The Technical Analyst
InVivo Therapeutics [NVIV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
InVivo Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-34.28% $0.321
America/New_York / 12 feb 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.996 mill |
| EPS: | -3.28 |
| P/E: | -0.0978 |
| Earnings Date: | Aug 08, 2023 |
| SharesOutstanding: | 3.11 mill |
| Avg Daily Volume: | 3.77 mill |
| RATING 2024-02-12 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0978 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.0978 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.128 - 0.392 ( +/- 50.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-05 | Foose Brice | Sell | 37 000 | InVivo Therapeutics Holdings Corp |
| 2023-02-05 | Foose Brice | Sell | 20 000 | InVivo Therapeutics Holdings Corp |
| 2023-02-05 | Foose Brice | Sell | 13 000 | InVivo Therapeutics Holdings Corp |
| 2023-02-05 | Foose Brice | Sell | 48 000 | InVivo Therapeutics Holdings Corp |
| 2023-02-05 | Foose Brice | Sell | 12 000 | InVivo Therapeutics Holdings Corp |
| INSIDER POWER |
|---|
| -77.00 |
| Last 96 transactions |
| Buy: 1 863 376 | Sell: 980 837 |
Forecast:
01:40 - $0.322
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.321 (-34.28% ) |
| Volume | 1.610 mill |
| Avg. Vol. | 3.77 mill |
| % of Avg. Vol | 42.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVIV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 7 - 10:20 | buy | $0.726 | N/A | Active |
|---|
NVIV
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2021-09-08 08:00:00 - Press Release
Invivo Therapeutics Announces 75% Target Enrollment Achieved For The Inspire 2.0 Spinal Cord Injury Study
Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the inspire 2.0 study, or 75% of the total 20-patient enrollment target for the study. the inspire 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
2021-07-06 08:05:00 - Press Release
Invivo Therapeutics Urges All Stockholders To Vote At The 2021 Annual Meeting To Be Held On Friday July 16, 2021
Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual annual meeting of stockholders is scheduled for friday, july 16, 2021 at 11 a.m., et and called on stockholders to vote to ensure that a quorum is present to hold the meeting and that the company's proxy proposals are passed. stockholders hol
2021-03-12 08:00:00 - Press Release
Invivo Therapeutics Announces Presentation At Upcoming M Vest Llc And Maxim Group Llc Inaugural Emerging Growth Virtual Conference
Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that richard toselli, m.d., president and chief executive officer, will present at the upcoming m vest llc and maxim group llc inaugural emerging growth virtual conference, which runs from march 17 – march 19 from 9:00 am – 5:00 pm et. dr. toselli's presentation will provi
2021-03-05 08:00:00 - Press Release
Invivo Therapeutics Announces Presentation At Upcoming 2021 H.c. Wainwright Global Life Sciences Conference
Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that richard toselli, m.d., president and chief executive officer, will present at the upcoming 2021 h.c. wainwright global life sciences conference. the conference is scheduled to be held march 9-10, 2021 in a virtual format. dr. toselli's presentation will provide an ove
2021-02-16 08:00:00 - Press Release
Invivo Therapeutics Announces Publication In Peer-reviewed Journal Of Neurosurgery: Spine
Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv) today announced the recent publication of a peer-reviewed manuscript in the journal of neurosurgery: spine describing the previously presented complete six-month primary endpoint results from the company's single-arm inspire 1.0 study (invivo study of probable benefit of the neuro-spinal scaffold™ for safety and neurologic recovery in subjects with complete thoracic ais a spinal cord injury), titled “a study of
Latest News
2022-10-07 10:25:51 - InvestorPlace
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
Source: ra2 studio/Shutterstock InVivo Therapeutics (NASDAQ: NVIV ) stock is on the move Friday after the company reached a deal for a direct offering of its shares. The registered direct offering has InVivo Therapeutics agreeing to sell 523,810 shares of NVIV stock to a single institutional investor.
2021-09-10 12:19:36 - InvestorPlace
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
2021-09-08 08:00:00 - Business Wire
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
2021-07-20 15:16:23 - PennyStocks
3 Biotech Penny Stocks That You Need to Know About In 2021
Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-14 13:39:48 - PennyStocks
Best Penny Stocks To Watch For July 2021
Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-13 15:43:49 - Pulse2
NVIV Stock Increases Over 36% Intraday: Why It Happened
The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.
2021-07-13 09:13:57 - Benzinga
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) application for its Neuro-Spinal Scaffold implant. Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions.
2021-07-06 08:05:00 - Business Wire
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual Annual Meeting of Stockholders is scheduled for Friday, July 16, 2021 at 11 a.m., ET and called on stockholders to vote to ensure that a quorum is present to hold the meeting and that the Company's proxy proposals are passed. Stockholders hol
2021-03-12 08:00:00 - Business Wire
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli's presentation will provi
2021-03-05 08:00:00 - Business Wire
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli's presentation will provide an ove